Last reviewed · How we verify
Bortezomib (Velcade®) (bortezomib-velcade)
Bortezomib (Velcade®) (generic name: bortezomib-velcade) is a Monoclonal antibody drug developed by Pfizer Inc.. It is currently in Phase 3 development.
At a glance
| Generic name | bortezomib-velcade |
|---|---|
| Sponsor | Pfizer Inc. |
| Modality | Monoclonal antibody |
| Phase | Phase 3 |
Approved indications
Common side effects
- Thrombocytopenia
- Diarrhoea
- Neutropenia
- Anaemia
- Nausea
- Fatigue
- Constipation
- Vomiting
- Pyrexia
- Neuropathy peripheral
- Decreased appetite
- Cough
Key clinical trials
- A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma (PHASE3)
- Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity (PHASE2)
- Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma (PHASE2)
- Bortezomib, Combination Chemotherapy, and Rituximab as First-Line Therapy in Treating Patients With Stage III or Stage IV Follicular Non-Hodgkin's Lymphoma (PHASE2)
- Bortezomib, Sorafenib Tosylate, and Decitabine in Treating Patients With Acute Myeloid Leukemia (PHASE1)
- Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma (PHASE1)
- Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma (PHASE3)
- Auto Transplant High Dose Melphalan vs High Dose Melphalan+Bortezomib in Pts With Multiple Myeloma Age 65 Years or Older (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bortezomib (Velcade®) CI brief — competitive landscape report
- Bortezomib (Velcade®) updates RSS · CI watch RSS
- Pfizer Inc. portfolio CI
Frequently asked questions about Bortezomib (Velcade®)
What is Bortezomib (Velcade®)?
Bortezomib (Velcade®) (bortezomib-velcade) is a Monoclonal antibody drug developed by Pfizer Inc..
Who makes Bortezomib (Velcade®)?
Bortezomib (Velcade®) is developed by Pfizer Inc. (see full Pfizer Inc. pipeline at /company/pfizer).
What is the generic name of Bortezomib (Velcade®)?
bortezomib-velcade is the generic (nonproprietary) name of Bortezomib (Velcade®).
What development phase is Bortezomib (Velcade®) in?
Bortezomib (Velcade®) is in Phase 3.
What are the side effects of Bortezomib (Velcade®)?
Common side effects of Bortezomib (Velcade®) include Thrombocytopenia, Diarrhoea, Neutropenia, Anaemia, Nausea, Fatigue.
Related
- Manufacturer: Pfizer Inc. — full pipeline
- Compare: Bortezomib (Velcade®) vs similar drugs
- Pricing: Bortezomib (Velcade®) cost, discount & access